La vendita allo scoperto per Nanoviricides dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Nanoviricides. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Nanoviricides (AMEX:NNVC) Azioni, Report sulle vendite allo scoperto

Nanoviricides

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

Nanoviricides Inc

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2024 with the Securities and Exchange Commission (SEC) on Friday, September 27, 2024. The report can be accessed at the SEC website (<a href="https://pr.report/33za">https://www.sec.gov/ix?doc=/Archives/edgar/data/1379006/000141057824001650/nnvc-20240630x10k.htm</a>).
We reported that, as of June 30, 2024, we had cash and cash equivalent current assets balance of approximately $4.97 Million. In addition, we reported approximately $7.5 Million in Net Property and Equipment (P&amp;E) assets (after depreciation). The strong P&amp;E assets comprise our cGMP-capable manufacturing and R&amp;D facility in Shelton, CT. The total current liabilities were approximately $1.36 Million. In comparison, as of June 30, 2023, we had cash and cash equivalent balance of approximately $8.15 Million, P&amp;E assets of approximately $8.1 Million (after depreciation), and total current liabilities of approximately $0.53 Million.
The net cash utilized in the reported period for operating activities was approximately $6.31 million that included certain expenditures for Phase Ia/Ib clinical trial of NV-387 and drug manufacturing costs for this clinical trial.
We raised approximately $3.12 million net of commission and certain expenses in an At-the-Market offering ("ATM") in the reported period at an average share price of $2.47.
With an additional raise of approximately $1.53 million subsequent to the period under the ATM, and an available line of credit that was increased to $3 million from $2 million provided by our founder and President Dr. Anil Diwan, we have approximately $9.5 million (approximately $8.1 million net of current liabilities) available for cash operational expenses going forward. As such, we reported that we do not have sufficient funding in hand to continue operations through September 30, 2025, for our planned objectives that include a Phase II clinical trial of NV-387 for RSV indication in the USA. As a result substantial doubt exists about the Company's ability to continue as a going concern, as evaluated based on applicable guidelines. We are actively exploring additional required funding through non-dilutive grants and contracts, partnering, debt or equity financing pursuant to our plan. We believe that the Company has on-going access to the capital markets including the "At-The-Market" (ATM) agreement that became active around April 5, 2024. We have perviously adjusted our objectives and development plans on the basis of available resources and we will continue to do so.
NV-387 - A Potentially Revolutionary Antiviral Drug that the Viruses are Unlikely to Escape
We have made significant progress in the regulatory advancement of NV-387. A Phase Ia/Ib clinical trial in healthy subjects was completed with all subjects discharged as of end of December, 2023. There were no adverse events reported. Lab data analysis is currently being conducted. We are awaiting a final report.
Additionally, we have made significant progress in expanding the indications of NV-387, that would result in substantial improvement in the return on investment when regulatory approvals are obtained.
Our host-mimetic, direct-acting, broad-spectrum, antiviral agent. NV-387 was found to have activity that surpassed the activity of known agents in lethal virus infection animal model trials for COVID, RSV, and Influenza.
In fact, we found that NV-387 treatment possibly completely cured the lethal RSV infection in mice, based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection. In particular, pediatric RSV infection treatment is an unmet medical need that we believe is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone.
NV-387 treatment was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu&#xAE;, Roche), peramivir (Rapivab&#xAE;, Biocryst), and baloxavir (Xofluza&#xAE;, Shionogi/Roche).
Additionally, NV-387 also demonstrated activity against lethal poxvirus infection animal models that was on par with the approved drug tecovirimat (TPOXX&#xAE;, SIGA).
NV-387 acts by a mechanism that is significantly different compared to the tested existing antiviral agents for Influenza and for Poxviruses.
This demonstrated broad-spectrum activity of NV-387 against widely varying viruses is because NV-387 is designed to attack the virus particle by mimicking sulfated proteoglycan (S-PG) feature, and all of these viruses are known to utilize heparan sulfate proteoglycans for gaining cell entry.
Further, for all of these tested viruses, even as the virus genome changes in the field, NV-387 is expected to continue to be effective, and the virus would be highly unlikely to escape NV-387. This is because despite all of the genomic changes, the virus continues to use HSPG, as is well known. Thus NV-387 solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all of the current antiviral tools that include vaccines, antibodies, and small chemical drugs.
Thus we anticipate that NV-387 would revolutionize the treatment of viral infections reminiscent of how penicillin revolutionized the treatment of bacterial infections.
Advancing NV-387 into Phase II Clinical Trials
In the ensuing year, we plan on advancing NV-387 into Phase II clinical trials. We believe that NV-387 qualifies under the MEURI WHO protocol to enter Phase II clinical trial for the treatment of MPOX disease that is a current epidemic in Central Africa (MEURI = Monitored Emergency Use of Unregistered and Investigational Interventions). This epidemic was declared a Public Health Emergency of International Concern (PHEIC) by the WHO in August, 2024. There is currently no drug available for treatment of MPOX since the clinical trial of tecovirimat did not demonstrate improvement in outcomes as compared to the standard of care, according to a press release by NIH in August, 2024.
We are also planning to advance NV-387 into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection.
We plan on advancing the regulatory processes for NV-387 registration for other indications such as influenza and COVID via partnerships and non-dilutive funding.
As we meet the milestones, we believe we will be able to raise financing for further regulatory activities for NV-387 registration via non-dilutive grant funding, partnership revenues, as well as equity-based funding.

News

NNVC

NanoViricides Advances NV-387 Antiviral Drug, Prepares for Phase II Clinical Trials for RSV and MPOX Treatment

WIIM

NanoViricides shares are trading higher after the company announced it obtained a right of first refusal for all antiviral drug developments from TheraCour Pharma.

NanoViricides, Inc. (NYSE American.:<a href="https://pr.report/2zzd">NNVC</a>) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first refusal (ROFR) for all antiviral drug developments from the R&amp;D firm TheraCour Pharma, Inc. ("TheraCour").
NanoViricides has signed a broad Memorandum of Understanding Agreement (MoU) with TheraCour encompassing all antiviral drugs developments on September 23, 2024, an important step that provides the Company certain intellectual property rights for developing treatments against any viral infections.
NV-387, the Company's lead drug, is proving to be a revolutionary drug that has demonstrated strong effectiveness, surpassing existing drugs, against a number of distinctly different types of viruses in animal studies. With this MoU in place, the increasing number of antiviral indications of a broad-spectrum drug such as NV-387 can be quickly and easily discovered and added by the Company to its portfolio of drugs in its development pipeline.
In addition to NV-387, certain "Trojan Horse" drugs that can completely cure most viral infections by attacking the virus lifecycle in multiple ways have been developed by the Company. This MoU expands NanoViricides Inc's abilities to opportunistically and rapidly develop such drugs to treat viral infections of public health importance, even for those viruses that don't exist today and cannot be predicted.
The new MoU provides NanoViricides with the ability to rapidly progress in such new endeavors and provides the important intellectual property rights to further develop multiple drug candidates towards a multitude of antiviral applications, many of which may have been previously considered to be intractable.
The MoU also codifies the process by which the two parties negotiate licenses to specific antiviral fields. As in the past, a license would not be restricted to a single drug, but rather would encompass all drugs that can be conceivably applicable with the R&amp;D performed against the licensed field of antiviral application.
The revolutionary nanoviricide technology resulting in host-mimetic, direct-acting antiviral drugs is opening up a new era of treating viral infections just as penicillin opened up a new era and revolutionized the treatment of bacterial infections, enabling "one drug - many bugs" model instead of the current "one bug - one drug" model. NV-387, an example of the capabilities of nanoviricide technology, was developed in 2020 in response to the COVID pandemic and has completed a Phase I human clinical trial successfully. The Company is now planning for NV-387 to enter into Phase II clinical trials for evaluation of its efficacy against several viral diseases that include RSV, Influenza, Bird Flu, COVID, as well as MPOX/Smallpox infections.

NanoViricides Secures First Rights To TheraCour's Antiviral Developments, Eyes Phase II Trials For Lead Drug

NanoViricides, Inc. <a href="https://pr.report/1ws6">(NYSE:</a><a href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it is investigating the possibility of using NV-387 for the treatment of MPOX patients under the WHO MEURI protocol, in light of the recent WHO PHEIC (Public Health Emergency of International Concern) declaration for the current 2024 MPOX outbreak that is rapidly spreading into more than ten countries in Africa with additional cases detected in Thailand and Sweden.
MEURI, i.e. Monitored Emergency Use of Unregistered and Investigational Interventions, is an ethical protocol developed by the World Health Organization to evaluate the potential use of experimental drugs in the event of public health emergencies (<a href="https://pr.report/1wrz">https://en.wikipedia.org/wiki/Monitored_Emergency_Use_of_Unregistered_and_Investigational_Interventions</a>).
The Company believes that the MEURI protocol may be applicable for the evaluation of NV-387 for the treatment of MPOX infection in patients. NV-387 has completed Phase I clinical trial for safety and tolerability studies in healthy subjects with no adverse events reported indicating excellent safety and tolerability. NV-387 has demonstrated strong improvement in survival in animal model studies matching that of the currently approved drug, tecovirimat, indicating excellent effectiveness. MPOX Clade 1/1b require development of new therapeutics due to limitations of existing therapies.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4">Survival Lifespan of Lethally Infected Mice - Intradigital Skin Footpad Infection with Ectromelia Virus (Model for MPOX, Smallpox)</td>
</tr>
<tr>
<td>Treatment</td>
<td>Survival, Days</td>
<td>Increase in Survival, Days</td>
<td>Increase in Survival, %</td>
</tr>
<tr>
<td>NV-387, Oral</td>
<td>14</td>
<td>6</td>
<td>75%</td>
</tr>
<tr>
<td>Tecovirimat, Oral</td>
<td>14</td>
<td>6</td>
<td>75%</td>
</tr>
<tr>
<td>NV-387-m-T, Oral</td>
<td>17</td>
<td>9</td>
<td>112.5%</td>
</tr>
<tr>
<td>Vehicle</td>
<td>8</td>
<td>0</td>
<td>0%</td>
</tr>
</tbody>
</table>
</figure>
Additionally, the Company has also found that NV-387 was superior to or equivalent to existing drugs in non-clinical animal trials in the case of three major classes of respiratory viruses: RSV, Influenza, and COVID; the so-called "triple-demic" respiratory viruses. The Company believes that NV-387, as a single broad-spectrum antiviral drug that can treat a large number of viruses, could be as revolutionary for the treatment of viral infections as penicillin was to bacterial infections, when its effectiveness is proven in human clinical trials.

NanoViricides Considers NV-387 for MPOX Treatment Under WHO Protocol Amid Global Outbreak

NanoViricides, Inc. <a href="https://pr.report/1nyr">(NYSE:</a><a href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities.
Dr. Anil Diwan, the Company's President, and Executive Chairman, is currently visiting with various expert professionals with the objective of developing a Phase II clinical trial plan and corresponding clinical protocol for a Phase II clinical trial of the drug candidate NV-387. The Company believes NV-387 is poised to become a revolutionary broad-spectrum antiviral treatment for infections from a number of viruses including RSV, COVID, and Influenzas, based on several animal studies.
Just three of the viruses addressed by this single drug NV-387, namely, Influenza, RSV and COVID, account for over $8 Billion in estimated market size in 2024, growing to an estimated $12 Billion in three years, as calculated by the Company from various market reports.
A successful Phase II clinical trial is expected to provide results demonstrating a strong effectiveness of NV-387 against different human pathogenic viruses, consistent with the strong effectiveness parameters found for NV-387 treatment of lethal virus challenge in various non-clinical animal model studies for RSV, COVID, Influenza, as well as Smallpox/Mpox.
With advice and opinions of experts, the Company is exploring the design of an innovative and ambitious, adaptive Phase II clinical trial wherein the effectiveness of the single drug NV-387 can be assessed for the treatment of a number of naturally occurring virus infections in humans in a single clinical trial.
In particular, the Company plans on exploring the effectiveness of NV-387 for the treatment of Severe Acute Respiratory Infections caused by Viruses ("SARI-Viral"). Most of such infections are caused by Influenza, RSV, and Coronaviruses, with a small extent of such infections being caused by other viruses including Adenoviruses, hMPV, and others.
If successful in such a clinical trial, NV-387 could become the very first drug that could be indicated as a first line treatment of any respiratory viral infections without having to wait for the results of testing for the type of virus, in a manner similar to how antibiotics can be prescribed by physicians at present.

NanoViricides' NV-387 Aims to Tackle RSV, COVID, and Flu in Upcoming Clinical Trials

Biotech

Health Care

General

NanoViricides Provides An Update On Its Clinical Program And Strategy In Its Letter To Shareholder, Says NV-387, An Antiviral Drug, Could Be As Revolutionary As Antibiotics

NanoViricides shares are trading higher after the company announced it discussed its development program for NV-387.

NanoViricides, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NYSE">NNVC</a>) (the "Company"), a clinical stage global leader in broad-spectrum antiviral nanomedicines, discusses its development program for NV-387, a single drug that has shown activity against many respiratory viral infections in animal models, enabling human clinical trials for a number of indications.
There are several viruses that continue to cause epidemics in humans; seasonal epidemics with Influenza, RSV, and SARS-CoV-2 (COVID) are occurring every year. The potential for severe Bird Flu pandemic, that may even be worse than the COVID-19 outbreak, is increasing every year as the virus spreads further into mammals and mutates more, according to experts.

NanoViricides Discusses Its Development Program For NV-387, Has Shown Activity Against Many Respiratory Viral Infections In Animal Models, Enabling Human Clinical Trials For A Number Of Indications

NanoViricides shares are trading higher after the company announced that it ultra-broad-spectrum antiviral NV-387 was found to be effective in protecting lungs from damage in a lethally infected Influenza A H3N2 mouse model.

Shares of Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>) fell sharply during Thursday's session <a href="https://www.benzinga.com/news/earnings/24/06/39411910/jabil-tops-q3-estimates-ceo-highlights-strategic-growth-in-ai-datacenters-and-ev-markets">following third-quarter results</a>.
Jabil reported third-quarter fiscal 2024 revenue of $6.77 billion, down by 20.2% year-on-year, beating the analyst consensus estimate of $6.53 billion. The print manufacturing company's adjusted EPS of $1.89 beat the analyst consensus of $1.85, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Jabil said it expects fourth-quarter revenue of $6.3 billion – $6.9 billion (consensus: $6.8 billion) and adjusted EPS to $2.03 – $2.43 (consensus: $2.22).
Jabil shares dipped 7.8% to $116.37 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>MGO Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares jumped 222.8% to $1.48 after the company said it expects the pending acquisition of Spetner Associates to close in the second half of 2024, projecting it to increase annualized revenue to approximately $28 million.</li>
<li>Griid Infrastructure Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRDI#NASDAQ">GRDI</a>) climbed 89.3% to $1.48 after falling more than 10% on Tuesday.</li>
<li>Zapp Electric Vehicles Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZAPP#NASDAQ">ZAPP</a>) gained 89% to $2.58 after the company said it expects first customer deliveries of the i300 in the fourth quarter and anticipates selling over 5,000 units in the fiscal year ending September 30, 2025.</li>
<li>Reliance Global Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) shares climbed 60.5% to $0.6279. Reliance Global Group announced major enhancement of capital structure following cashless exercise of warrants.</li>
<li>Allurion Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALUR#NYSE">ALUR</a>) gained 50% to $1.598. Allurion announced publication of new data demonstrating lean mass gains in patients experiencing 14% weight loss.</li>
<li>SMX (Security Matters) Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) rose 43% to $0.1702 after jumping 19% on Tuesday.</li>
<li>Soluna Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNH#NASDAQ">SLNH</a>) gained 23.3% to $5.96.</li>
<li>Femasys Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) rose 22% to $1.1650 after receiving CE Mark approval from the EU MDR for its FemaSeed, FemVue, FemCerv, and FemCath products.</li>
<li>Molecular Partners AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) shares rose 21.1% to $9.63 after gaining 9% on Tuesday.</li>
<li>Surf Air Mobility Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRFM#NASDAQ">SRFM</a>) jumped 20.6% to $0.3850.</li>
<li>ToughBuilt Industries, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLT#NASDAQ">TBLT</a>) gained 20.2% to $3.75.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) surged 19.7% to $1.1303. MicroCloud Hologram entered into convertible note purchase agreements with investors for $28 million on June 18.</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) shares climbed 19.2% to $0.0877after falling around 5% on Tuesday.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) gained 16.5% to $1.91. Nanoviricides reported that the ultra-broad-spectrum antiviral NV-387, a Phase 2 Stage drug candidate, was found to be effective in protecting lungs from damage in a lethally infected influenza H3N2 mouse model.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) rose 16.4% to $2.47.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 16% to $6.36 after TD Cowen upgraded the stock from Hold to Buy and raised its price target from $7 to $11.</li>
<li>Applied Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLD#NASDAQ">APLD</a>) jumped 15.3% to $5.95.</li>
<li>Ranpak Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) climbed 13.7% to $6.49.</li>
<li>ImmunityBio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBRX#NASDAQ">IBRX</a>) rose 13.6% to $7.08 after the company announced insurance coverage of ANKTIVA across multiple states with first commercial doses administered.</li>
<li>Harrow, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HROW#NASDAQ">HROW</a>) gained 12.2% to $19.81 after the company announced the manufacture of the first of three commercial-scale process performance qualification batches of TRIESENCE 40 mg/mL. Also the company announced that the second and third required PPQ batches are now scheduled.</li>
<li>ZKH Group Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZKH#NYSE">ZKH</a>) rose 11.4% to $3.92</li>
<li>NANO Nuclear Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNE#NASDAQ">NNE</a>) gained 11.3% to $12.91.</li>
<li>Himax Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIMX#NASDAQ">HIMX</a>) jumped 11.1% to $8.23</li>
<li>UTime Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) surged 11% to $0.5849</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) gained 10% to $1.1450. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on &#8216;Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.&#8217;</li>
<li>Bilibili Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BILI#NASDAQ">BILI</a>) shares climbed 7.8% to $17.45. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.</li>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) gained 7% to $982.60 after Elon Musk indicated the company will provide server racks for the supercomputer that xAI is building.</li>
<li>Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) rose 5% to $162.36.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 43.7% to $0.1993. Trevena announced preclinical TRV045 data for long-term analgestic effect in prelinical model of neuropathic pain. Also, the company announced TRV045 results provided director for additional NIH-initiated studies in epilepsy prevention and treatment.</li>
<li>Kaival Brands Innovations Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares declined 33.5% to $2.99 after gaining 8% on Tuesday.</li>
<li>Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) fell 29% to $1.10. Sonnet BioTherapeutics announced exercise of warrants for gross proceeds of $3.4 million.</li>
<li>Tempest Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) declined 25% to $2.1208. The company announced new data from the ongoing Phase 1b/2 clinical study on amezalpat2 (TPST-1120).</li>
<li>Nikola Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKLA#NASDAQ">NKLA</a>) declined 23.6% to $0.3672. Nikola announced 1-for-30 reverse stock split approved by board.</li>
<li>La Rosa Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LRHC#NASDAQ">LRHC</a>) shares fell 23.5% to $1.37. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.</li>
<li>SYLA Technologies Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYT#NASDAQ">SYT</a>) dipped 21.7% to $1.70.</li>
<li>Mustang Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares dipped 21% to $0.6721 after the company announced a $2.5 million registered direct offering of 6.130 million shares at $0.41 per share.</li>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) fell 20.9% to $72.55.</li>
<li>NLS Pharmaceutics AG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NLSP#NASDAQ">NLSP</a>) tumbled 20.3% to $0.1910 after jumping 82% on Tuesday.</li>
<li>DermTech, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMTK#NASDAQ">DMTK</a>) fell 19.4% to $0.1176.</li>
<li>Dunxin Financial Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXF#NASDAQ">DXF</a>) shares fell 19.4% to $0.1728 after dipping 17% on Tuesday.</li>
<li>Tempus AI, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>) fell 15.1% to $25.76 amid post-IPO volatility.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) declined 15% to $2.2991 after B of A Securities downgraded the stock from Neutral to Underperform.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) shares fell 13.7% to $0.2150. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) fell 12.2% to $1.8602. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft&#8217;s public sector distributor.</li>
<li>Jasper Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) declined 10.1% to $20.84. Jasper Therapeutics announced appointment of Svetlana Lucas Ph.D., to its Board of Directors.</li>
<li>GMS Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) declined 6.5% to $84.02 after the company reported mixed fourth-quarter financial results.</li>
<li>Nayax Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NYAX#NASDAQ">NYAX</a>) fell 6.1% to $21.23.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) fell 5% to $6.03 after the company&#8217;s board determined that recent takeover proposals were not in its best interests.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39411935/this-skyworks-solutions-analyst-turns-bullish-here-are-top-5-upgrades-for-thursday">This Skyworks Solutions Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday</a>

Intraday Update

Markets

Movers

Trading Ideas

ALUR

APLD

ASNS

BILI

DMTK

ESPR

FEMY

GRDI

HIMX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

IBRX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KAVL

LOBO

LRHC

MBIO

MGOL

MOLN

NKLA

NLSP

NYAX

OCUL

PACK

PRST

RELI

SLNH

SMCI

SONN

SRFM

SVMH

TBLT

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

VNDA

ZAPP

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) stock rose 39.1% to $11.07 during Thursday's regular session. The market value of their outstanding shares is at $367.3 million. </li>
<li>Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) stock rose 36.83% to $5.67. The market value of their outstanding shares is at $402.2 million. </li>
<li>Femasys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FEMY#NASDAQ">FEMY</a>) stock increased by 28.27% to $1.23. The market value of their outstanding shares is at $27.2 million. </li>
<li>SeaStar Medical Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICU#NASDAQ">ICU</a>) shares rose 18.68% to $4.89. The market value of their outstanding shares is at $15.2 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) shares rose 17.68% to $1.93. The company's market cap stands at $22.8 million. </li>
<li>CASI Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>) shares rose 17.22% to $3.13. The company's market cap stands at $41.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares declined by 28.9% to $0.6 during Thursday's regular session. The market value of their outstanding shares is at $17.0 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) stock declined by 28.9% to $0.25. The company's market cap stands at $4.6 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares declined by 27.47% to $1.11. The market value of their outstanding shares is at $3.4 million. </li>
<li>Tempest Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPST#NASDAQ">TPST</a>) stock fell 25.79% to $2.12. The market value of their outstanding shares is at $46.9 million. </li>
<li>VYNE Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYNE#NASDAQ">VYNE</a>) stock decreased by 21.72% to $1.73. The company's market cap stands at $25.1 million. </li>
<li>Alaunos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCRT#NASDAQ">TCRT</a>) shares fell 21.7% to $0.65. The market value of their outstanding shares is at $10.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CASI

TCRT

VYNE

ZNTL

12 Health Care Stocks Moving In Thursday's Intraday Session

Nanoviricides Reports That The Ultra-broad-spectrum Antiviral NV-387, A Phase 2 Stage Drug Candidate, Was Found To Be Effective In Protecting Lungs From Damage In A Lethally Infected Influenza H3N2 Mouse Model

Shares of AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) fell sharply during Friday's session <a href="https://www.benzinga.com/quote/POWW/earnings">following fourth-quarter results</a>.
AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for a loss of 1 cent per share. The company reported quarterly sales of $40.42 million topping estimates of $37.90 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AMMO shares dipped 19.1% to $2.0306 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Kaival Brands Innovations Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KAVL#NASDAQ">KAVL</a>) shares jumped 345% to $6.06.</li>
<li>SRIVARU Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVMH#NASDAQ">SVMH</a>) gained 150% to $0.3852 after the company announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.</li>
<li>CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) surged 42.5% to $5.16.</li>
<li>FOXO Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXO#NASDAQ">FOXO</a>) shares gained 29% to $0.3092 after the company announced it entered into share exchange agreements with Rennova Health.</li>
<li>Jeffs&#8217; Brands Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFBR#NASDAQ">JFBR</a>) surged 29% to $0.4528.</li>
<li>BIMI Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) gained 25.7% to $2.15.</li>
<li>Longeveron Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) rose 23.4% to $3.36.</li>
<li>OneMedNet Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) gained 20% to $1.4599 as the company announced iRWD customer data license agreement with a leading U.S.-based global clinical trial design and software company.</li>
<li>Can-Fite BioPharma Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANF#NYSE">CANF</a>) jumped 17.9% to $4.28.</li>
<li>Disc Medicine, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) rose 15.6% to $45.29. Disc Medicine announced a $178 million underwritten offering of 4.944 million shares at $36 per share.</li>
<li>Adobe Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) rose gained 14.3% to $524.39 following better-than-expected second-quarter earnings and strong guidance.</li>
<li>RenovoRx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) surged 14.3% to $1.2001.</li>
<li>Ocular Therapeutix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) gained 14.1% to $5.75 as the company highlighted AXPAXLI SOL-1 enrollment and plans repeat dosing study in wet AMD.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 14% to $0.1836 after dipping 17% on Thursday.</li>
<li>VinFast Auto Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFS#NASDAQ">VFS</a>) gained 9.9% to $4.32. VinFast Auto anticipates sustained growth for next five years and approaching break-even point.</li>
<li>Tutor Perini Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPC#NYSE">TPC</a>) rose 9.9% to $21.11. UBS analyst Steven Fisher upgraded Tutor Perini from Neutral to Buy and raised the price target from $14 to $27.</li>
<li>Willis Lease Finance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) gained 6.4% to $64.99.</li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) gained 5.5% to $61.22 after B of A Securities upgraded the stock from Neutral to Buy and raised its price target from $70 to $80.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares dipped 43.3% to $116.47 after announcing a $3.5 billion private placement.</li>
<li>Nexalin Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 33.3% to $0.9192 after jumping 121% on Thursday. Nexalin Technology recently announced regulatory approval of Gen-2 15mA neurostimulation device by Brazilian Health Regulatory Agency.</li>
<li>IN8bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) dipped 31.1% to $1.1598 after the company presented data from its Phase 1 trial of INB-100 showing 100% of treated leukemia patients achieved durable complete remission at 1 year.</li>
<li>Gain Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) fell 28.1% to $1.3599 after the company announced the pricing of a $11 million public offering of 7,116,547 shares at $1.35 per share and pre-funded warrants.</li>
<li>Kyverna Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) dipped 24.8% to $10.88.</li>
<li>Rezolute, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) shares fell 24.3% to $3.90 after the company announced pricing of public offering of $60 million of common stock and pre-funded warrants.</li>
<li>ThermoGenesis Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) dipped 20.2% to $0.3302.</li>
<li>NaaS Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAAS#NASDAQ">NAAS</a>) fell 20.2% to $5.66. The company announced completion of ADS ratio change.</li>
<li>NanoViricides, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#NASDAQ">NNVC</a>) fell 19.3% to $2.08</li>
<li>Neo-Concept International Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCI#NASDAQ">NCI</a>) shares fell 19.2% to $0.7141 after jumping over 35% on Thursday.</li>
<li>Ostin Technology Group Co Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) fell 19.2% to $0.4020 after jumping 24% on Thursday.</li>
<li>RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) shares fell 18.6% to $225.60 after the company reported mixed first-quarter financial results.</li>
<li>Assure Holdings Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONM#NASDAQ">IONM</a>) declined 15.3% to $0.26.</li>
<li>Bandwidth Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BAND#NASDAQ">BAND</a>) fell 13.1% to $16.07. Morgan Stanley analyst Meta Marshall downgraded Bandwidth from Equal-Weight to Underweight and lowered the price target from $18 to $15.</li>
<li>Cabaletta Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CABA#NASDAQ">CABA</a>) dipped 12.5% to $10.99 as the company announced initial clinical data from Phase 1/2 RESET-Myositis and RESET-SLE trials of CABA-201.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) fell 10.5% to $6.11.</li>
<li>Corcept Therapeutics Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) dipped 10% to $28.36.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) fell 9.7% to $13.59.</li>
<li>PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) fell 9.6% to $17.23. Truist Securities analyst Barry Jonas maintained PENN Entertainment with a Buy and raised the price target from $23 to $25.</li>
<li>ATI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATI#NYSE">ATI</a>) fell 9.6% to $51.65.</li>
<li>MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) shares declined 8.3% to $77.48 after the company reported preliminary third-quarter financial results below estimates and cut its FY24 adjusted operating margin.</li>
<li>Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>) fell 7.7% to $39.82 as the company announced the pricing of public offering of common stock and pre-funded warrants.</li>
<li>WESCO International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCC#NYSE">WCC</a>) fell 7.1% to $161.79.</li>
<li>Carnival plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUK#NYSE">CUK</a>) fell 6.7% to $13.89.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) fell 5.7% to $14.23.</li>
<li>Telephone and Data Systems, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDS#NYSE">TDS</a>) fell 5.6% to $18.93</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39331763/dell-palo-alto-networks-and-2-other-stocks-insiders-are-selling">Dell, Palo Alto Networks And 2 Other Stocks Insiders Are Selling</a>

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KITT

KYTX

LGVN

NAAS

NVAX

ONMD

PENN

POWW

RARE

RNXT

RZLT

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) shares moved upwards by 37.4% to $2.9 during Friday's regular session. The market value of their outstanding shares is at $7.2 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock rose 35.86% to $4.92. The market value of their outstanding shares is at $1.9 million. </li>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares moved upwards by 23.23% to $3.31. The market value of their outstanding shares is at $21.0 million. </li>
<li>iSpecimen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPC#NASDAQ">ISPC</a>) stock moved upwards by 19.44% to $0.49. The market value of their outstanding shares is at $4.8 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) stock rose 17.8% to $3.32. The market value of their outstanding shares is at $1.9 million. </li>
<li>Disc Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRON#NASDAQ">IRON</a>) shares increased by 17.59% to $46.05. The company's market cap stands at $1.1 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock fell 36.2% to $0.88 during Friday's regular session. The company's market cap stands at $6.5 million. </li>
<li>Kyverna Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KYTX#NASDAQ">KYTX</a>) shares decreased by 34.46% to $9.46. The market value of their outstanding shares is at $408.0 million. </li>
<li>Gain Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GANX#NASDAQ">GANX</a>) shares fell 32.29% to $1.28. The company's market cap stands at $23.1 million. </li>
<li>IN8bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INAB#NASDAQ">INAB</a>) shares declined by 30.06% to $1.18. The company's market cap stands at $51.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) shares declined by 25.39% to $1.93. The company's market cap stands at $22.7 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock declined by 21.9% to $4.03. The market value of their outstanding shares is at $161.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CYCN

ISPC

SCNI

12 Health Care Stocks Moving In Friday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Longeveron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGVN#NASDAQ">LGVN</a>) shares rose 112.1% to $1.74 during Wednesday's regular session. The market value of their outstanding shares is at $11.0 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock increased by 43.09% to $26.0. The market value of their outstanding shares is at $63.2 million. </li>
<li>Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) shares increased by 32.32% to $38.27. The company's market cap stands at $3.6 billion. </li>
<li>Cyclerion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCN#NASDAQ">CYCN</a>) stock rose 30.39% to $2.96. The company's market cap stands at $7.3 million. </li>
<li>Telesis Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBIO#NASDAQ">TBIO</a>) stock moved upwards by 22.53% to $3.86. The company's market cap stands at $6.4 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 20.94% to $1.42. The market value of their outstanding shares is at $26.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>ThermoGenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THMO#NASDAQ">THMO</a>) shares fell 31.4% to $0.38 during Wednesday's regular session. The market value of their outstanding shares is at $3.0 million. </li>
<li>TRACON Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCON#NASDAQ">TCON</a>) shares decreased by 25.92% to $0.8. The company's market cap stands at $2.1 million. </li>
<li>Streamline Health Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STRM#NASDAQ">STRM</a>) shares declined by 21.86% to $0.5. The market value of their outstanding shares is at $31.0 million. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock fell 21.76% to $2.59. The market value of their outstanding shares is at $30.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares fell 16.67% to $0.23. The market value of their outstanding shares is at $14.4 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 16.16% to $1.61. The company's market cap stands at $2.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AVGR

CLDI

STRM

TBIO

TCON

VTVT

12 Health Care Stocks Moving In Wednesday's Intraday Session

A First-In-Class, Broad-Spectrum Antiviral Agent Intending To Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More

NanoViricides' NV-387 Results Show Flat Blood Concentration Profile For Prolonged Antiviral Effect In Clinical Trials

<h3>Gainers</h3>
<ul>
<li>Seres Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) stock moved upwards by 34.0% to $0.82 during Monday's regular session. The company's market cap stands at $124.5 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares increased by 32.51% to $1.71. The market value of their outstanding shares is at $252.1 million. </li>
<li>Champions Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSBR#NASDAQ">CSBR</a>) shares increased by 22.82% to $5.65. The company's market cap stands at $76.8 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock rose 22.02% to $3.26. The market value of their outstanding shares is at $38.4 million. </li>
<li>Semler Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMLR#NASDAQ">SMLR</a>) stock moved upwards by 20.13% to $38.0. The market value of their outstanding shares is at $268.5 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) stock moved upwards by 18.63% to $1.3. The company's market cap stands at $8.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) stock fell 35.6% to $0.36 during Monday's regular session. The company's market cap stands at $6.8 million. </li>
<li>Tharimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THAR#NASDAQ">THAR</a>) stock fell 31.74% to $3.55. The company's market cap stands at $2.7 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock decreased by 27.83% to $3.65. The company's market cap stands at $1.1 million. </li>
<li>Curis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRIS#NASDAQ">CRIS</a>) stock fell 19.58% to $7.11. The company's market cap stands at $41.9 million. </li>
<li>Skye Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYE#NASDAQ">SKYE</a>) stock fell 15.0% to $9.3. The market value of their outstanding shares is at $261.0 million. </li>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) shares decreased by 14.62% to $15.52. The company's market cap stands at $2.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRIS

CSBR

MCRB

RENB

RNAZ

SBFM

SKYE

SMLR

THAR

12 Health Care Stocks Moving In Monday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million. </li>
<li>PACS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACS#NYSE">PACS</a>) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares increased by 0.95% to $0.21. The company's market cap stands at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Matinas BioPharma Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MTNB#AMEX">MTNB</a>) shares decreased by 4.2% to $0.15 during Wednesday's after-market session. The market value of their outstanding shares is at $38.7 million. </li>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) stock declined by 3.19% to $0.27. The company's market cap stands at $4.6 million. </li>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) stock fell 2.66% to $1.1. The company's market cap stands at $47.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares fell 2.4% to $6.51. The market value of their outstanding shares is at $341.1 million. </li>
<li>Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) stock declined by 2.28% to $0.43. The company's market cap stands at $228.2 million. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) stock declined by 2.16% to $0.35. The company's market cap stands at $61.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZTR

MPLN

MTNB

OGEN

PACS

RBOT

SENS

TOVX

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Concord Medical Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCM#NYSE">CCM</a>) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) stock increased by 4.26% to $0.21. The market value of their outstanding shares is at $10.8 million. </li>
<li>Anitra (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#AMEX">AZTR</a>) shares moved upwards by 2.69% to $0.18. The market value of their outstanding shares is at $5.0 million. </li>
<li>MAIA Biotechnology (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#AMEX">MAIA</a>) stock rose 0.79% to $3.79. The company's market cap stands at $82.7 million. </li>
<li>Emergent BioSolutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>) shares moved upwards by 0.53% to $5.59. The market value of their outstanding shares is at $292.9 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) shares increased by 0.38% to $0.24. The market value of their outstanding shares is at $64.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock fell 4.7% to $0.4 during Tuesday's after-market session. The market value of their outstanding shares is at $28.0 million. </li>
<li>SunLink Health Systems (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SSY#AMEX">SSY</a>) shares declined by 3.8% to $0.68. The company's market cap stands at $4.7 million. </li>
<li>Scorpius Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SCPX#AMEX">SCPX</a>) shares fell 3.55% to $0.12. The market value of their outstanding shares is at $11.8 million. </li>
<li>MultiPlan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPLN#NYSE">MPLN</a>) shares decreased by 1.19% to $0.47. The market value of their outstanding shares is at $300.1 million. </li>
<li>IGC Pharma (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IGC#AMEX">IGC</a>) shares fell 0.97% to $0.47. The company's market cap stands at $35.4 million. </li>
<li>Nanoviricides (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NNVC#AMEX">NNVC</a>) shares decreased by 0.78% to $2.4. The company's market cap stands at $28.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASXC

MAIA

PHGE

SCPX

12 Health Care Stocks Moving In Tuesday's After-Market Session

<ul>
<li>The Company has found that its lead nanoviricide broad-spectrum antiviral drug candidate NV-387, when given as a slow bolus intravenous infusion, resulted in a relatively flat plateau of blood concentration of the drug with very slow decline over a 24 hour period in a cynomolgus monkey model.</li>
<li>The maximum concentration as well as the plateau concentration increased in a dose-dependent manner, as expected.</li>
</ul>

NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model

NanoViricides (NNVC) has released an update. NanoViricides, Inc. has revised its License Agreement with TheraCour Pharma, Inc., deferring cash mile...

NanoViricides Restructures Agreements to Alleviate Financial Stress

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Investors should keep their eyes on the <a href="https://www.globenewswire.com/news-release/2023/12/07/2792336/0/en/Global-Nanotechnology-Market-Size-To-Exceed-USD-74-1-Billion-By-2032-CAGR-of-34-5.html">global nanotechnology market</a>, which was valued at USD 3.78 billion in 2022 and is expected to reach USD 74.1 billion by 2032, growing at a CAGR of 34.5% during the forecast period. The growth is attributed to the increasing adoption of nanotechnology in various industries such as electronics &amp; semiconductor, automobiles, and more, leading to a boom for nanotech stocks.



 The nanodevice segment dominates the market with a 53.6% revenue share, while the healthcare &amp; pharmaceuticals segment accounts for the largest revenue share of 32.8%. North America leads the market with a 34.7% share, followed by Asia Pacific, which is expected to grow at the fastest rate moving forward.



Given the fast-growing nature of the industry, I believe there are some nanotech stocks that could make lucky investors millionaires overnight. These firms are deniably risky and speculative, but they could pay off in spades if the right conditions are met.



So here are three nanotech stocks that could mint new millionaires overnight.



<h2>NanoViricides (NNVC)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/12/nanorobot-300x169.jpg" alt="A concept image of nanorobots for medical use."><div>Source: Shutterstock</div></div>NanoViricides (NYSE:<a href="https://investorplace.com/stock-quotes/nnvc-stock-quote/">NNVC</a>) develops antiviral therapies utilizing nanotechnology. The company reported the <a href="https://ca.finance.yahoo.com/quote/NNVC/">successful completion</a> of its Phase 1a/1b clinical trial for NV-CoV-2, its broad-spectrum antiviral drug. The trial, focusing on COVID-19 treatment, showed no adverse events. In 2024, NanoViricides aims to <a href="https://ca.finance.yahoo.com/quote/NNVC/">continue advancing NV-CoV-2</a> through further clinical trials, expanding its treatment capabilities to address unmet medical needs. The company&rsquo;s stock has seen moderate volatility, with analysts setting a price target of $6.50, which is more than a 400% implied upside at the time of writing.



Additionally, NanoViricides has expanded its pipeline, developing therapies for various viral infections, including respiratory syncytial virus (RSV), shingles, and other enveloped viruses&#8203;. The biotech industry is volatile and risky enough without throwing nanotech into the mix, but it may also significantly enhance NNVC&rsquo;s upside.



These firms are all or nothing proposition, exactly what an investor wants in a company for this type of risk.



<h2>Luna Innovations (LUNA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2020/02/laser_optics_1600-300x169.jpg" alt="A photo of a purple and green laser going through an object"><div>Source: science photo / ShutterStock.com</div></div>Luna Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/luna-stock-quote/">LUNA</a>) focuses on advanced technology solutions, including fiber optic sensing systems and nanotechnology for various industries. 



The company <a href="https://ir.lunainc.com/news-releases/news-release-details/luna-innovations-reports-second-quarter-2023-results">reported revenue growth</a>, with total revenue for the nine months ended Sept. 30, 2023, increasing to $84.9 million, up 9% from the previous year. However, net loss from continuing operations was $1.9 million, though adjusted EBITDA was $7.8 million, indicating some operational progress&#8203;.



For 2024, Luna aims to strengthen its technological advancements in fiber optic sensing systems and other areas, reaffirming its position in the market&#8203;.



This nanotech stock has shown volatility, but analysts forecast a positive outlook, with a consensus price target of $10. This gives it an upside of over 380% at the time of writing.



Furthermore, its tiny market cap of just $69 million and negative earnings makes it especially risky. However, its also that needed juice required to mint new millionaires overnight.



<h2>Nano Dimension (NNDM)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2021/03/nndm-stock-1600-300x169.jpg" alt="Nano Dimension (NNDM stock) logo in an iPad, on the background their proprietary 3D printer"><div>Source: Spyro the Dragon / Shutterstock.com</div></div>Nano Dimension (NASDAQ:<a href="https://investorplace.com/stock-quotes/nndm-stock-quote/">NNDM</a>) provides 3D printing solutions for electronics, incorporating nanotechnology for innovative manufacturing.<a href="https://investorplace.com/stock-quotes/-stock-quote/"></a>



3D printing was all the rage before AI swept up the speculative dollars flowing into it. NNDM could still be a multibagger, and it&rsquo;s a slightly less speculative company compared with the other firms listed.



The <a href="https://investors.nano-di.com/press-releases/news-details/2024/Nano-Dimension-Announces-Record-2023-Revenue-of-56.3-Million-and-Organic-Growth-of-29/default.aspx">company&rsquo;s revenue for 2023</a> reached $56.3 million, marking a 29% increase compared to 2022&#8203;. In Q1 2024, Nano Dimension reported consolidated revenues of approximately $13.2 million. The company also achieved a significant reduction in cash burn, decreasing by 75% compared to Q1 2023.



Nano Dimension has been expanding its strategic initiatives, particularly through mergers and acquisitions, while also pursuing share repurchase programs&#8203;. For 2024, the company aims to continue consolidating its position in the additive manufacturing market, with a focus on improving its operational efficiency and profitability. This includes plans for continued growth in its core business areas and capital allocation to support its multi pronged strategy.



On the date of publication, Matthew Farley did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed are those of the writer, subject to the<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"> InvestorPlace.com Publishing Guidelines</a>.
<div>Matthew started writing coverage of the financial markets during the crypto boom of 2017 and was also a team member of several fintech startups. He then started writing about Australian and U.S. equities for various publications. His work has appeared in MarketBeat, FXStreet, Cryptoslate, Seeking Alpha, and the New Scientist magazine, among others.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/05/3-nanotech-stocks-with-the-potential-to-make-you-an-overnight-millionaire/">3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

3 Nanotech Stocks With the Potential to Make You an Overnight Millionaire

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon

NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers

XBP and MNTX among mid-day movers

NanoViricides, TC BioPharm, Holdco Nuvo among healthcare movers

NanoViricides GAAP EPS of -$0.16

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Nanoviricides (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nnvc-stock-quote/">NNVC</a>) just reported results for the third quarter of 2024.<ul><li>Nanoviricides reported earnings per share of -16 cents. This was above the analyst estimate for EPS of -19 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/nnvc-stock-earnings-nanoviricides-for-q3-of-2024/">NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

NNVC Stock Earnings: Nanoviricides Beats EPS for Q3 2024

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday morning as we dive into all of the hottest news affecting shares this morning!



Moving stocks this morning are heaving trading, earnings reports, a stock offering and more.



Let&rsquo;s get into this news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Virax Biolabs (NASDAQ:<a href="https://investorplace.com/stock-quotes/vrax-stock-quote/">VRAX</a>) stock is rocketing close to 158% alongside heavy pre-market trading.</li>



<li>Aethlon Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/aemd-stock-quote/">AEMD</a>) shares are soaring more than 94% with strong early morning trading.</li>



<li>Logistic Properties (NYSEMKT:<a href="https://investorplace.com/stock-quotes/lpa-stock-quote/">LPA</a>) stock is surging over 50% after <a href="https://www.nasdaq.com/press-release/logistic-properties-americas-ring-opening-bell-new-york-stock-exchange-2024-05-30">recently going public</a>.</li>



<li>Nauticus Robotics (NASDAQ:<a href="https://investorplace.com/stock-quotes/kitt-stock-quote/">KITT</a>) shares are gaining more than 27% with heavy trading this morning.</li>



<li>iSpecimen (NASDAQ:<a href="https://investorplace.com/stock-quotes/ispc-stock-quote/">ISPC</a>) stock is increasing over 25% with strong trading on Thursday morning.</li>



<li>Nanoviricides (NYSEMKT:<a href="https://investorplace.com/stock-quotes/nnvc-stock-quote/">NNVC</a>) shares are rising nearly 19% without any clear news on Thursday.</li>



<li>60 Degrees (NASDAQ:<a href="https://investorplace.com/stock-quotes/sxtp-stock-quote/">SXTP</a>) stock is heading 18% higher despite a lack of news this morning.</li>



<li>Vanda Pharmaceuticals(NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/">VNDA</a>) shares are climbing more than 16% as it takes part in a <a href="https://www.nasdaq.com/press-release/vanda-pharmaceuticals-announces-participation-jefferies-2024-global-healthcare">global healthcare conference starting today</a>.</li>



<li>Motorsport Games (NASDAQ:<a href="https://investorplace.com/stock-quotes/msgm-stock-quote/">MSGM</a>) stock is jumping over 15% after <a href="https://www.nasdaq.com/press-release/motorsport-games-regains-compliance-nasdaq-listing-rules-2024-06-05">regaining listing compliance</a>.</li>



<li>8&times;8 (NASDAQ:<a href="https://investorplace.com/stock-quotes/eght-stock-quote/">EGHT</a>) shares are up more than 14% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Actelis Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/asns-stock-quote/">ASNS</a>) stock is plummeting almost 45% <a href="https://investorplace.com/2024/06/why-is-actelis-networks-asns-stock-up-689-today/">after a massive rally yesterday</a>.</li>



<li>Jowell Global (NASDAQ:<a href="https://investorplace.com/stock-quotes/jwel-stock-quote/">JWEL</a>) shares are diving over 23% after a major rally on Wednesday.</li>



<li>Sprinklr (NYSE:<a href="https://investorplace.com/stock-quotes/cxm-stock-quote/">CXM</a>) stock is tumbling more than 21% after <a href="https://www.nasdaq.com/press-release/sprinklr-announces-first-quarter-fiscal-2025-results-and-appoints-trac-pham-co-chief">cutting its revenue outlook</a>.</li>



<li>Fresh2 Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/fres-stock-quote/">FRES</a>) shares are taking a 19% beating after rallying in the prior day of trading.</li>



<li>MicroAlgo (NASDAQ:<a href="https://investorplace.com/stock-quotes/mlgo-stock-quote/">MLGO</a>) stock is sliding over 17% as it <a href="https://investorplace.com/2024/06/why-is-microalgo-mlgo-stock-up-162-today/">comes off of a recent rally</a>.</li>



<li>Helius Medical Tech (NASDAQ:<a href="https://investorplace.com/stock-quotes/hsdt-stock-quote/">HSDT</a>) shares are dropping more than 17% despite <a href="https://www.nasdaq.com/press-release/microcap-rodeos-spring-summer-conference-june-6th-2024-25-presenting-companies-2024">taking part in a conference today</a>.</li>



<li>InMed Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/inm-stock-quote/">INM</a>) stock is falling close to 17% on Thursday morning.</li>



<li>Nuvve (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvve-stock-quote/">NVVE</a>) shares are decreasing over 16% after a rally yesterday.</li>



<li>Renalytix (NASDAQ:<a href="https://investorplace.com/stock-quotes/rnlx-stock-quote/">RNLX</a>) stock is slipping more than 16% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318376664&amp;type=PDF&amp;symbol=RNLX&amp;cdn=50b6d5e78c92d2a587a022cdac0add19&amp;companyName=Renalytix+plc&amp;formType=S-3&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-05">proposed secondary stock sale</a>.</li>



<li>Five Below (NASDAQ:<a href="https://investorplace.com/stock-quotes/five-stock-quote/">FIVE</a>) shares close out our pre-market stock movers down over 16% after <a href="https://finance.yahoo.com/news/five-below-five-q1-earnings-211505510.html">missing Q1 estimates</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-6th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

Nanoviricides

Vendite allo scoperto

Nanoviricides (AMEX:NNVC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO